Tag Archives: biotech regulation

Americans, Biotech Execs, Convention Attendees Optimistic About Biotech

Key Findings From A  National Survey Of Voters

What does the future hold for biotechnology? After surveying American voters, biotech executives, and attendees here the 2012 BIO International Convention, we learned that the future is indeed bright.  More than three quarters of American voters, nearly all the biotech execs, and 1,400 of the attendees we spoke to are optimistic that science and technology will find cures to help patients suffering from serious diseases, such as cancer, diabetes, Alzheimer’s, Parkinson’s and HIV/AIDS. Tempering that Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Industry Regulatory Issues to be Highlighted at 2012 BIO International Convention

bio-session

In the words of BIO’s Andrew Emmett, Managing Director, Science & Regulatory Affairs, ‘2012 is shaping up to be a momentous year for FDA reform.’ From the reauthorization of the Prescription Drug User Fee Act (PDUFA V) to modernizing and expediting the approval of new drugs and biologics, implementing the new biosimilars pathways and addressing the growing global drug shortage crisis, all eyes are on the current regulatory environment and its role in supporting innovation. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

2012: A Critical Year for Biotechnology

Capitol

In 2012, we must continue to look for ways to reduce risk; enhance reward; reduce uncertainty; and reinforce the position of the industry as a major contributor resolving society’s most pressing needs. Policies to encourage investment in innovation and to speed discovery to scientific breakthroughs simply must be the priority in 2012. The industry relies on a policy and regulatory environment that encourages innovation for much needed treatments and cures for some of the most Read More >

Public Policy  |  1 Comment  |  Email This Post
Tags: , , , , , ,

Medical Innovation at Risk

Scientists

The National Venture Capital Association’s MedIC Coalition recently released a report showing U.S. venture capitalists are decreasing their investments in biopharmaceutical and medical device companies, reducing their concentration in prevalent disease areas and shifting investments towards Europe and Asia. The report, Vital Signs: The Threat to Investment in U.S. Medical Innovation and the Imperative of FDA Reform, strongly indicates that America’s medical innovation economy is in grave danger of losing its primary source of funding, Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

How we are advancing American innovation to cure disease and save lives

JimGreenwood

Mankind’s need to cure disease, combat hunger and discover new forms of energy has never been more urgent. Yet despite the extraordinary hope offered by biotechnology to solve these problems, government policies and the capital formation environment necessary to support these goals are insufficiently conducive to allowing us to meet these critical challenges. During our 2011 BIO International Convention, we unveiled a strategic initiative to speed scientific breakthroughs, develop cures and grow the bio-economy. The Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,